This figure is not a marketing assertion
Pattappa G, Krueckel J, Schewior R, Franke D, Mench A, Koch M, Weber J, Lang S, Pfeifer CG, Johnstone B, Docheva D, Alt V, Angele P, Zellner J
These genetic insights may help provide context for why certain compounded formulations and dosing strategies align better with your metabolic profileand how medication selection affects long-term cost-effectiveness
If anything looks different from this guide, pause and contact your prescriber or pharmacist
Use of GLP-1 agonists is increasing both through NHS and private prescriptions
Months 10-12 Long-term planning Focus on sustaining whole-body health and consider next steps for your GLP-1 therapy